MediChem CEO Looks to Expand Proteomics Effort | GenomeWeb

NEW YORK, May 22 – After launching into proteomics last year with the acquisition of Emerald BioStructures and ThermoGen, combinatorial chemistry specialist MediChem is now planning to delve even deeper into the study of proteins, MediChem CEO Michael Flavin said Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.